Fig. 1 · Structure

Documents & Downloads

U0126-EtOH

Cat. No. A10957 CAS 1173097-76-1

MEK inhibitor

U0126-EtOH is an inhibitor of both MEK1 and MEK2 with an IC50 of 72 nM and 58 nM respectively.

In Stock

Publications for U0126-EtOH

5 publications citing this product

  1. Ji Wang, .et al. , Acta Pharmacol Sin, 2024, Nov 20 PMID: 39567750
  2. Hanna Galganska, .et al. , Cell Mol Life Sci, 2021, Dec;78(24):8229-8242 PMID: 34741187
  3. Paul Mark Medina, .et al. , Transl Oncol, 2021, Jan;14(1):100940 PMID: 33221682
  4. Byungki Jang, .et al. , Int J Mol Sci, 2017, Nov; 18(11): 2258 PMID: 29077055
  5. Choe YJ, .et al. , Int J Oncol., 2014, 44(3):761-8. PMID: 24366007

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

U0126 is used to interrogate MEK–ERK signaling. In HepG2 cells, the A10957 reagent at 800 nM reduced ERK1/2 phosphorylation. This cellular endpoint supports pathway inhibition; it does not establish direct binding, isolated-enzyme potency or direct ERK inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
MEK2 IC50 0.06μM
MEK1 IC50 0.07μM
PKC IC50 >10μM
CDK2 IC50 >10μM
CDK4 IC50 >10μM
MKK6/p38MAPK IC50 20μM
MKK3/p38MAPK IC50 38μM
ERK1/2 IC50 >50μM
JNK IC50 >100μM
MKK4 IC50 >100μM
Abl IC50 >100μM

11 targets · Scroll to view more

In Vitro Studies

In HepG2 cells, 800 nM U0126 increased CYP7A1 mRNA after 0.5 h pretreatment and an additional 10 h treatment. In a separate EA.hy926 experiment using A10957, a condition labeled MEK1/2 inhibitors prevented TNFα-induced ERK1/2 phosphorylation while CO2-induced activation persisted. Its caption specifies U0126 (2.5 µM) and PD98059 (25 µM), without separate single-agent responses, so the latter effects cannot be assigned to U0126 alone. [1,2]

U0126 alters ERK phosphorylation and CYP7A1 expression in HepG2 cells

Cell-based study · Human HepG2 hepatoma cells [1]

At 800 nM, U0126 reduced phospho-ERK1/2 signal and increased CYP7A1 mRNA relative to the U0126-negative condition. This is one cell-treatment design with two related endpoints, not direct inhibition of isolated ERK enzyme.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ERK1/2 phosphorylationqualitative comparison Reduced with U0126[1]
CYP7A1 mRNA expressionqualitative comparison Increased; **P < 0.01[1]

Literature-Reported Treatment Conditions

Treatment concentration
800 nM
Exposure duration
0.5 h pretreatment followed by an additional 10 h treatment (Fig. 6d,e caption)
Method
HepG2 cell treatment; cells serum-starved for 10 h before subsequent treatment in shared methods.
Co-treatment
No co-treatment is indicated for the U0126 +/- comparison in Fig. 6d,e.
Reported limits
U0126 vehicle and exact biological n for Fig. 6d,e are not specified in the acquired text/caption. Global statement: experiments repeated at least twice; qPCR triplicate analyses are technical replicates, not a biological n.
Methods and source locations

Compound reported in the paper: U0126; Compound label in the paper: Adooq Bioscience A10957

Evidence for the paper-reported A10957 reagent; no current lot, purity, stereochemical or solvate validation and no salt/form conversion.

Fig. 6d,e (image and caption); Materials and methods: Reagents, Cell culture and treatment, Quantitative real-time PCR, Western blotting, Statistical analysis; Results: FGF21-induced ERK activity mediated the Cyp7a1 induction by BCAAs

ERK1/2 phosphorylation: Western blot for phospho-ERK1/2, total ERK1/2 and β-actin — Fig. 6d; Western blotting

CYP7A1 mRNA expression: qPCR normalized to 18S RNA; mean ± SEM; two-sided Student t-test for two-group comparisons — Fig. 6e; Quantitative real-time PCR; Statistical analysis

Stimulus-dependent ERK phosphorylation under the reported MEK-inhibitor condition

Cell-based study · Human EA.hy926 endothelial cell line [2]

The condition labeled MEK1/2 inhibitors prevented TNFα-induced ERK1/2 phosphorylation, while a CO2-induced increase persisted. The caption lists U0126 and PD98059, without separate single-agent responses; the effect cannot be assigned to U0126 alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phospho-ERK1/2 response to TNFα versus CO2qualitative comparison TNFα-induced response prevented; CO2-induced activation not abolished[2]

Literature-Reported Treatment Conditions

Treatment concentration
U0126 2.5 µM; PD98059 25 µM
Exposure duration
0 and 5 min stimulus time points in Fig. 1e; inhibitor preincubation time is not specified for this panel.
Method
EA.hy926 cells exposed to 10% CO2 or 10 ng/mL TNFα under the MEK1/2-inhibitor condition.
Vehicle
PBS and/or DMSO controls specified in shared cell-culture methods; exact panel-specific fraction not stated.
Co-treatment
Fig. 1e shows one condition labeled MEK1/2 inhibitors and the caption specifies U0126 2.5 µM and PD98059 25 µM. No separate single-agent lanes are identifiable; simultaneous versus otherwise grouped use is not explicitly distinguished in the selected text.
Reported limits
Cannot isolate the contribution of U0126 from PD98059 or establish simultaneous versus grouped use from the panel. Inhibitor preincubation time and panel-specific vehicle fraction are not specified in the acquired selected text.
Methods and source locations

Compound reported in the paper: U0126; Compound label in the paper: Adooq Bioscience A10957

Evidence for the paper-reported A10957 reagent; no current lot, purity, stereochemical or solvate validation and no salt/form conversion.

Fig. 1e (image, condition labels, full caption); Materials and methods: Cell culture, Immunoblotting, Statistical analysis; Results: ERK1/2 are activated by CO2 in vitro and in human cells

Phospho-ERK1/2 response to TNFα versus CO2: Phospho-ERK1/2 immunoblotting and densitometry; total ERK1/2, GAPDH and Ponceau S loading controls; mean ± SD of three independent experiments — Fig. 1e; full Fig. 1 caption; Statistical analysis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1173097-76-1
Applications MEK inhibitor
Formula C18H16N6S2.C2H6O
Molecular Weight 426.6
SMILES
CCO.C1=CC=C(C(=C1)N)S/C(=C(/C(=C(/SC2=CC=CC=C2N)\N)/C#N)\C#N)/N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 77 mg/mL (180.51 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4.03 mg/mL
Vehicle
5%DMSO+40%PEG300+5%Tween 80+50%H2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wang J, Zhong MY, Liu YX, et al. Branched-chain amino acids promote hepatic Cyp7a1 expression and bile acid synthesis via suppressing FGF21-ERK pathway Acta pharmacologica Sinica (2025). PMID: 39567750 DOI: 10.1038/s41401-024-01417-2 Source material
  2. [2] Galganska H, Jarmuszkiewicz W, Galganski L. Carbon dioxide inhibits COVID-19-type proinflammatory responses through extracellular signal-regulated kinases 1 and 2, novel carbon dioxide sensors Cellular and molecular life sciences : CMLS (2021). PMID: 34741187 DOI: 10.1007/s00018-021-04005-3 Source material

Publications

5 publications citing this product

  1. Ji Wang, .et al. , Acta Pharmacol Sin, 2024, Nov 20 PMID: 39567750
  2. Hanna Galganska, .et al. , Cell Mol Life Sci, 2021, Dec;78(24):8229-8242 PMID: 34741187
  3. Paul Mark Medina, .et al. , Transl Oncol, 2021, Jan;14(1):100940 PMID: 33221682
  4. Byungki Jang, .et al. , Int J Mol Sci, 2017, Nov; 18(11): 2258 PMID: 29077055
  5. Choe YJ, .et al. , Int J Oncol., 2014, 44(3):761-8. PMID: 24366007

Added to your cart

View Cart Checkout
Loading...